Biosafety and Safety by Design: Identifying Adventitious Agents in Cell & Gene Therapy Production

Introduction Cell and gene therapies (CGTs) are an important growth sector for the biopharmaceutical industry. The US Food and Drug Administration (FDA) has now approved several CGTs for use in humans. CGT has, however, highlighted deficiencies in traditional safety models, reinforcing the need for ...

To read the full article and other articles in this issue, please register for a free account or log in.

We will not sell or give your information to a third party. See our Privacy Policy



Subscribe to our FREE newsletter

We will not sell or give your information to a third party. See our Privacy Policy